共 50 条
- [1] EGFR signaling as a mechanism of resistance to CDK4/6 inhibitors in Palbociclib-resistant ER plus breast cancer cellsCANCER RESEARCH, 2022, 82 (12)Lypova, NadiiaLanceta, LilibethDougherty, Susan M.Chesney, Jason A.Imbert-Fernandez, Yoannis
- [2] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancerNATURE COMMUNICATIONS, 2019, 10 (1)Formisano, LuigiLu, YaoServetto, AlbertoHanker, Ariella B.Jansen, Valerie M.Bauer, Joshua A.Sudhan, Dhivya R.Guerrero-Zotano, Angel L.Croessmann, SarahGuo, YanEricsson, Paula GonzalezLee, Kyung-MinNixon, Mellissa J.Schwarz, Luis J.Sanders, Melinda E.Dugger, Teresa C.Cruz, Marcelo RochaBehdad, AmirCristofanilli, MassimoBardia, AdityaO'Shaughnessy, JoyceNagy, Rebecca J.Lanman, Richard B.Solovieff, NadiaHe, WeiMiller, MichelleSu, FeiShyr, YuMayer, Ingrid A.Balko, Justin M.Arteaga, Carlos L.
- [3] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependenceONCOGENE, 2017, 36 (16) : 2255 - 2264Yang, C.Li, Z.Bhatt, T.Dickler, M.Giri, D.Scaltriti, M.Baselga, J.Rosen, N.Chandarlapaty, S.
- [4] Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependenceOncogene, 2017, 36 : 2255 - 2264C YangZ LiT BhattM DicklerD GiriM ScaltritiJ BaselgaN RosenS Chandarlapaty
- [5] Acquired sensitivity strategies in ER plus breast cancer progressing on CDK4/6 and mTOR inhibitorsCANCER RESEARCH, 2022, 82 (04)Farmaki, EleniEmond, RenaCosgrove, PatrickBild, Andrea
- [6] Unveiling mechanisms of CDK4/6 inhibitor resistance in ER plus breast cancer models with acquired resistanceCANCER RESEARCH, 2024, 84 (06)Li, BinLiu, GaoxiangNi, TingShi, WentingGu, Qingyang
- [7] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancerCANCER GENE THERAPY, 2022, 29 (06) : 859 - 869Kharenko, Olesya A.Patel, Reena G.Calosing, Cyrusvan der Horst, Edward H.
- [8] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancerCancer Gene Therapy, 2022, 29 : 859 - 869Olesya A. KharenkoReena G. PatelCyrus CalosingEdward H. van der Horst
- [9] Mechanisms of resistance to CDK4/6 inhibition in ER plus breast cancerCANCER RESEARCH, 2016, 76Lee, N. V.Eisele, K. J.Chionis, J.Yuan, J.Zhu, Z.Liu, C.Li, D.Olson, P. A.Fantin, V.Arndt, K. T.Shields, D. J.VanArsdale, T. L.
- [10] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerNature Communications, 10Luigi FormisanoYao LuAlberto ServettoAriella B. HankerValerie M. JansenJoshua A. BauerDhivya R. SudhanAngel L. Guerrero-ZotanoSarah CroessmannYan GuoPaula Gonzalez EricssonKyung-min LeeMellissa J. NixonLuis J. SchwarzMelinda E. SandersTeresa C. DuggerMarcelo Rocha CruzAmir BehdadMassimo CristofanilliAditya BardiaJoyce O’ShaughnessyRebecca J. NagyRichard B. LanmanNadia SolovieffWei HeMichelle MillerFei SuYu ShyrIngrid A. MayerJustin M. BalkoCarlos L. Arteaga